キナーゼ阻害剤がゲートキーパー残基変異にどう抵抗するか
Jagannath Mondal1, Pratyush Tiwary2, B J Berne2
1Tata Institute of Fundamental Research, Center for Interdisciplinary Sciences, Hyderabad, India.
Journal of the American Chemical Society
|March 9, 2016
まとめ
ゲートキーパー変異は 癌の薬剤耐性を引き起こします この研究は,より良い薬剤設計のための高度なシミュレーションを使用して,II型阻害剤RL45が抵抗を克服し,I型阻害剤ダサチニブが失敗する理由を示しています.
科学分野:
- 生物化学
- コンピュータ生物学
- 薬理学について
背景:
- キナーゼゲートキーパー変異は がん治療に抵抗性を与える.
- 癌の効果的な治療には,突然変異に抵抗するキナーゼ阻害剤の開発が不可欠です.
研究 の 目的:
- T338Mゲートキーパー変異によって引き起こされるcSrcキナーゼ阻害剤に対する耐性の背後にある分子機構を調査する.
- この変異に対するタイプI (ダサチニブ) とタイプII (RL45) 阻害剤の有効性を原子模擬を用いて比較する.
主な方法:
- 強化されたサンプリング技術,特にレプリカ交換溶質テンプレート (FEP/REST) を利用した.
- 阻害剤-キナーゼの相互作用の熱力学および構造的性質を分析するために原子学的シミュレーションを行った.
主要な成果:
- ダサチニブは野生型cSrcに好ましい結合を示したが,T338M変異体には好ましくない結合を示した.
- RL45は,ワイルドタイプとT338M変異キナーゼの両方に好ましい結合を示した.
- ダサチニブの失敗は,水素結合の喪失と不柔軟なリングによるステリック障害に起因する.
- RL45の成功はフェニル環の柔軟性とフェニララニンとの良好な静電相互作用に関連している.
結論:
- RL45は構造の柔軟性により,cSrc T338Mゲートキーパー変異を効果的に克服します.
- 強化されたサンプリングシミュレーションにより,薬剤耐性メカニズムに関する正確な洞察が得られます.
- この研究は 次世代の変異抵抗性キナーゼ阻害剤の設計に役立ちます
関連する概念動画
Amplifying Signals via Enzymatic Cascade
19.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
19.2K
Protein Kinases and Phosphatases
15.5K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.5K
Protein Kinases and Phosphatases
4.7K
4.7K
The JAK-STAT Signaling Pathway
13.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
13.8K
PI3K/mTOR/AKT Signaling Pathway
6.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.2K
Inhibition of Cdk Activity
6.2K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K


